Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies biomarkers in tumor tissue samples from patients with rhabdomyosarcoma.
Genetic: gene expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: mass spectrometry
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||A Study to Assess and Quantify Surface Insulin-like Growth Factor I Receptor (IGF-IR) in Rhabdomyosarcoma (RMS) Tumor Tissue|
- Degree of surface IGF-IR expression in RMS tumor tissue [ Designated as safety issue: No ]
- Feasibility and validity of a mass spectrometry assay for IGF-IR expression on paraffin-embedded tumor tissue [ Designated as safety issue: No ]
|Study Start Date:||June 2011|
|Estimated Primary Completion Date:||January 2100 (Final data collection date for primary outcome measure)|
- To determine and quantify the degree of surface insulin-like growth factor I receptor (IGF-IR) expression in rhabdomyosarcoma (RMS) tumor tissue.
- To assess the feasibility and validity of a mass spectrometry assay for IGF-IR expression on paraffin-embedded tumor tissue.
OUTLINE: Paraffin-embedded tumor tissue slides are analyzed for insulin-like growth factor I receptor (IGF-1R) expression by mass spectrometry and correlated with the results obtained by IHC assay.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01365962
|Principal Investigator:||Suman Malempati, MD||Doernbecher Children's Hospital at Oregon Health and Science University|